Vera Therapeutics (VERA) Stock Outlook: December 11, 2025 Update on Public Offering, Atacicept BLA and Wall Street Targets
Vera Therapeutics, Inc. (NASDAQ: VERA) is back center stage on December 11, 2025, as traders digest a fresh equity offering, strong late‑stage clinical data, and a newly filed Biologics License Application (BLA) for its lead drug, atacicept, in IgA nephropathy